Tanzania TMDA accelerated registration: how WHO PQ Indian generics reach Dar es Salaam in 90 days, not 18 months.

Tanzania's Medicines and Medical Devices Authority offers Indian generic exporters one of the most pragmatic regulatory shortcuts in East Africa: products with WHO Prequalification status, or filed against the WHO PQ Collaborative Procedure for Accelerated Registration, can move from dossier submission to local marketing authorisation in 90 days. The same product without that overlay sits in the standard queue for 18 to 24 months. Same molecule, same manufacturer, same dossier. The difference is which procedural lane the file enters. For HIV antiretrovirals, anti-TB lines, anti-malarials and a defined set of essential medicines, the accelerated lane is the rational choice. Here is how it actually works.

What the TMDA accelerated pathway is.

TMDA, the Tanzania Medicines and Medical Devices Authority, headquartered in Dodoma with a Dar es Salaam office, is the national medicines regulator. It replaced the older Tanzania Food and Drugs Authority (TFDA) in 2019 when food safety was moved to a separate authority. TMDA registers pharmaceuticals, biologicals, medical devices and diagnostic reagents for the Tanzanian mainland; the semi-autonomous regulator on Zanzibar runs separately under the ZFDA.

The accelerated registration pathway is TMDA's adoption of the WHO Collaborative Registration Procedure for products that already carry WHO Prequalification status, plus an internal fast-track for a defined essential-medicines list and for products responding to declared public-health priorities. Both lanes feed into a 90-day commitment from administrative-validation to marketing-authorisation issuance, against the 18-to-24 month wall-clock of the standard pathway.

The accelerated lane is administrative rather than scientific: TMDA accepts the WHO PQ technical assessment as the substantive review, reviews the dossier for Tanzanian-specific labelling and pricing compliance, and issues the local MA on that basis. It is not a rubber stamp; the dossier still has to be complete and the local-side requirements have to be met. But the technical review is not re-litigated.

Why it exists: Tanzania's Global Fund and PEPFAR exposure.

Tanzania is one of the highest-volume Global Fund and PEPFAR procurement countries in East Africa. HIV antiretrovirals, anti-TB fixed-dose combinations, anti-malarials and reproductive health commodities flow through the national medical-stores system in nine-figure annual volumes. Donor procurement insists on WHO Prequalified product. The accelerated registration pathway is TMDA's way of saying: if the product already meets the WHO PQ bar, we will not be the bottleneck.

The practical consequence: every Indian manufacturer holding WHO PQ for an HIV ARV, an anti-TB FDC, or an artemisinin combination therapy can reach the Tanzanian public-sector market through the accelerated lane. Without WHO PQ, the same manufacturer queues for 18-24 months in the standard lane and watches Global Fund tender cycles pass.

Eligibility: what counts as WHO Prequalified.

Three eligibility routes feed the TMDA accelerated lane. Manufacturers should know which one their product travels under, because the dossier requirements vary.

• WHO PQ-listed finished product. The molecule and dosage form is on the current WHO Prequalification list at extranet.who.int/prequal/. The MA number, manufacturer name and site address must match the WHO PQ listing exactly. Mismatches are the most common deficiency.
• WHO Collaborative Registration Procedure. The product is not yet listed but is in active WHO PQ assessment, and the manufacturer has signed the WHO Collaborative Registration consent allowing WHO to share its technical assessment with the national regulator. TMDA accepts this route.
• Stringent Regulatory Authority approval. Products carrying US FDA, EU EMA, UK MHRA, Health Canada, TGA Australia or PMDA Japan approval qualify under TMDA's reliance pathway, even without WHO PQ. The review is slightly longer than the WHO PQ route but still inside the accelerated lane.

What does not qualify: CDSCO India approval alone, GCC-registration approval alone, or WHO-GMP-only credentials. These are valid for the standard pathway but do not unlock the 90-day commitment.

90 days standard vs 18-24 months default.

The accelerated lane calendar, for an eligible product with a complete dossier:

1. Pre-submission, 2-4 weeks. Tanzania local representative appointed (a TMDA-licensed pharmaceutical wholesaler), pricing file prepared, English-language labelling artwork drafted, WHO PQ documentation harvested.
2. Submission and administrative validation, 5-15 days. TMDA's electronic registration system accepts the dossier. Administrative completeness check happens here; missing pieces bounce the file before the 90-day clock starts.
3. Substantive review against the WHO PQ assessment, 30-45 days. TMDA reviewers verify that the product, manufacturer, site and dosage form align with the cited WHO PQ assessment, and that local labelling, pricing and post-marketing-surveillance commitments are present.
4. Final approval and MA issuance, 15-30 days. The MA certificate is issued in the local representative's name. Total from submission to MA: 90 days for clean files; 120-150 days when deficiency cycles are needed.

The standard pathway, for products without WHO PQ or SRA overlay, runs 18-24 months: 30-60 days administrative validation, 12-15 months scientific review by TMDA's in-house assessors, 60-90 days deficiency cycles, 30-60 days MA issuance. Same dossier authoring effort. Very different commercial impact.

The Indian-side documentation pack.

For an Indian WHO-PQ-listed product entering the TMDA accelerated lane, the dossier pack is administrative-heavy and short on novel scientific content. The technical content travels via TMDA's access to the WHO PQ assessment; the dossier itself proves the product matches the WHO PQ listing and meets Tanzanian-specific requirements.

The Indian-end pack:

• WHO PQ confirmation letter from the WHO Prequalification Team, current (issued within 12 months) and naming the manufacturer, the dosage form and the MA number.
• CDSCO Certificate of Pharmaceutical Product (CoPP) in WHO format, apostilled by the Indian Ministry of External Affairs and legalised at the Tanzanian High Commission.
• WHO-GMP certificate for the manufacturing site and the specific dosage form. The site address must match the WHO PQ listing.
• Form 25/28 CDSCO manufacturing licence, notarised.
• Site Master File excerpt, particularly the production-flow and quality-control sections.
• Stability summary referenced to ICH Zone IVb (30°C / 75% RH), matching the WHO PQ stability commitment.
• Sample SmPC, PIL and outer-carton artwork in English, with Tanzanian-specific elements: TMDA registration number placeholder, local representative name and address, Tanzanian Shilling pricing block on outer carton.
• Supply commitment letter from the manufacturer to the Tanzanian local representative, naming forecast quantities for the first 24 months.
• Pharmacovigilance contact: a named Tanzanian local representative employee, with a backup at the manufacturer's QA team in India.

The MSD plus MEMS-CSSC buyer channels.

The Tanzanian pharmaceutical market splits into three buyer channels, and an Indian supplier sequencing market entry should understand which is which.

• Medical Stores Department (MSD), headquartered in Dar es Salaam with 10 regional zonal stores. MSD is the public-sector consolidator. Global Fund, PEPFAR and Government of Tanzania-funded HIV ARV, anti-TB, anti-malarial and reproductive health commodities flow through MSD framework tenders. Highest volume; lowest margin; long payment cycles (90-180 days are common); MA on the dossier and price on the bid are what wins.
• MEMS (Mission for Essential Medical Supplies) and CSSC (Christian Social Services Commission) handle faith-based and mission-hospital procurement. Smaller volumes than MSD, faster payment, more relationship-driven. A good MEMS/CSSC framework slot is the warm-up for an MSD bid.
• Private wholesalers and pharmacy chains (Pharmaplus, Bhanji Khanji, Shree Hindu) handle private retail and small private hospitals. Smallest volumes per SKU, highest margins, fastest payment. Useful for non-WHO-PQ specialty lines that do not qualify for accelerated registration anyway.

Mumbai to Dar es Salaam cold-chain reality.

Mumbai to Dar es Salaam Julius Nyerere International (DAR) is approximately 8-9 hours wheels-up direct via Kenya Airways, RwandAir or Ethiopian Airlines, sometimes via Nairobi or Addis Ababa. Sea freight from Nhava Sheva to Dar es Salaam runs 18-22 days transit, the dominant mode for ambient-temperature finished pharma.

Cold-chain via air freight requires Dar es Salaam ground-handling cold-chain capacity, which exists but is not as deep as Nairobi NBO. For temperature-controlled biologicals, routing via Nairobi with road transfer to Dar can be more reliable than direct DAR airside for sensitive products. The trade-off is 24-48 hours of additional transit against a more validated cold-chain handover.

Customs clearance at DAR for fully-documented MA-registered pharma runs 5-10 working days. New importers see longer windows; established Tanzanian local representatives with a track record see 3-5 days.

Where the accelerated review still stalls.

The 90-day commitment assumes a clean file. Four places where the clock pauses or the accelerated lane closes:

1. WHO PQ listing mismatch. The most common cause of deficiency. The manufacturer name, site address, MA number and dosage form on the Indian dossier must match the WHO PQ listing exactly. Site address that reads "Plot 14, Village" on WHO PQ and "Plot 14/A, Village" on the CDSCO licence triggers a deficiency cycle. Pre-flight cross-check is the discipline.
2. Apostille missing or wrong. The CDSCO CoPP needs Indian MEA apostille AND Tanzanian High Commission legalisation. One without the other does not satisfy TMDA. The legalisation step alone takes 2-3 weeks if the Tanzanian High Commission in New Delhi is the route.
3. Local representative not currently TMDA-licensed. The named local representative on the dossier must hold a current TMDA wholesale licence. Lapsed licences void the application. Some Indian manufacturers use representatives without verifying the licence status quarterly.
4. Pricing block missing on the artwork. Tanzanian outer-carton artwork must carry a price block in Tanzanian Shillings. Submitting artwork without the price block, or with a wrong-currency placeholder, triggers a labelling deficiency. The price itself is filed separately with the pricing committee; only the artwork compliance is checked at registration.

One additional point about post-marketing surveillance: TMDA expects an annual Periodic Safety Update Report submission for newly registered products in the first three years. The PSUR is the local representative's filing, prepared by the manufacturer's QA team in India to ICH E2C format. Missing the PSUR window is the most common reason a five-year-old registration loses its renewal.

FAQ

Does an Indian manufacturer need a Tanzanian office to use the TMDA accelerated pathway?

No. The manufacturer needs a Tanzanian local representative (a TMDA-licensed pharmaceutical wholesaler) who is the named filer of the dossier and the holder of the marketing authorisation. The local representative can be a third-party Tanzanian importer, not necessarily an entity owned by the manufacturer. The manufacturer remains the supplier of record on the CoPP and the WHO-GMP certificate.

What is the difference between TMDA accelerated and a fully-recognised WHO PQ approval?

TMDA accelerated is a national marketing authorisation issued by Tanzania, based on TMDA's acceptance of the WHO PQ technical assessment. The product is registered in Tanzania, can be imported and sold there, and is procurable by MSD, MEMS, CSSC and private channels. A WHO PQ approval is a UN-level product certification that any donor (Global Fund, PEPFAR, UNICEF) can procure against. Different scopes; the same Indian dossier feeds both.

How long does the WHO PQ listing itself take, for a manufacturer that does not yet hold it?

The WHO Prequalification process for an Indian generic typically runs 18-30 months from submission to listing, including the dossier review, the GMP inspection of the manufacturing site and any deficiency cycles. The Collaborative Registration Procedure exists for products mid-assessment, allowing the dossier to be filed in Tanzania once the WHO PQ assessment is signed-off but before the formal listing is published. The CRP route can shave 6-12 months off the wait.

How does TMDA registration compare with neighbouring Kenya and Uganda?

Kenya's Pharmacy and Poisons Board (PPB) and Uganda's National Drug Authority (NDA) both have accelerated lanes for WHO PQ products, with similar 90-180 day commitments. The Indian-side dossier is largely interchangeable across the three; the local-side requirements (representative licensing, pricing-file format, language conventions) differ. A manufacturer planning East Africa entry typically files Kenya first (largest tender market), Tanzania second (highest WHO PQ alignment), and Uganda third (Global Fund volume per capita is highest of the three). Kenya PPB, Tanzania TMDA, and the broader Africa hub have the country pages.